Axsome Therapeutics (NASDAQ: AXSM) Secures Global Rights to Balipodect for Neuropsychiatric Treatment
Expert Analysis Axsome Therapeutics (NASDAQ: AXSM) has strategically expanded its pipeline with the acquisition of balipodect, a selective phosphodiesterase 10A inhibitor. This move underscores the company’s commitment to innovating treatments for schizophrenia and related neuropsychiatric disorders. Balipodect’s mechanism positions it as potentially the first in its class, offering promising therapeutic differentiation. The integration of this novel compound could enhance Axsome Therapeutics’ portfolio and provide new avenues to address unmet medical…
